GlassScriptPhysician profile
Jonathan Manuel Dominguez
NPI 1376923755
$30,073.09
in general payments reported to CMS, 2019-2025
56 companies · $2,751 in 2025
The $2,751 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,557 · 2020: $9,056 · 2021: $3,845 · 2022: $2,935 · 2023: $2,377 · 2024: $5,552 · 2025: $2,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,659 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,659.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,032.08 | 2019-2020 | |
| Abbvie INC. | $6,616.00 | 2019-2025 | Qulipta, Linzess, Viberzi |
| Amgen INC. | $2,743.71 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $1,672.90 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,086.58 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $1,084.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,011.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $908.28 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $888.77 | 2019-2025 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $863.26 | 2019-2025 | Xifaxan, Trulance, Cycloset |
| Ironwood Pharmaceuticals, INC | $549.28 | 2019-2023 | Linzess |
| Janssen Pharmaceuticals, INC | $543.71 | 2019-2023 | Spravato, Xarelto |
| Madrigal Pharmaceuticals | $485.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Amarin Pharma, INC. | $446.80 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $441.09 | 2024-2025 | Voquezna |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Dominguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.